RxDoctor Payments Data

Bethany Lewallen

Optometrist · Dover, DENPI 1366416026

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $994 of the $1,197 with a category attached, or 83.0%. 13 manufacturers reported payments, led by Alcon at 35.7% of the total.

$1,197in general payments, 2019–2025

Across 36 payments — averaging $33.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$427
  • Coopervision Inc.$257
  • Sun Pharmaceutical Industries Inc.$190
  • AbbVie$58
  • Harrow Eye, LLC$50
  • Bausch & Lomb Americas Inc.$47
  • plus $169 from 7 others

What the payments were for

  • Speaking & faculty fees$20417%
  • Food & beverage$99483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,197 in reported general payments places this provider in the 65th percentile of 146 optometrist providers in Delaware.

See all optometrist providers in Delaware

Medicare billing

Part B allowed, 2024
$145,956
Medicare patients
709
Services billed
1,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast28$32,576
RestasisCyclosporine18$15,153
Travoprost27$8,303
MieboPerfluorohexyloctane/Pf11$8,005
Brimonidine Tartrate29$6,057
Latanoprost214$5,435
TafluprostTafluprost/Pf18$4,000
Cyclosporine11$3,571
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,523
Timolol Maleate51$1,452
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$835
Doxycycline Monohydrate12$417
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha29$395
ErythromycinErythromycin Base25$263
Dorzolamide Hcl18$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$47$40,58139 claims
AbbVieRestasis$58$15,15318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 146 optometrist providers in Delaware.

Other optometrist in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →